4th Quarter - Report

MEDSECUREAN.COM for LUPIN PHARMACEUTICALS

Period 4th Quarter 2025 Filed Feb 14, 2026 Signed by Kathleen D Jaeger

Official filing
Firm
MEDSECUREAN.COM
Client
LUPIN PHARMACEUTICALS
Income
$42,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Generic Industry Sustainability and tariifs broadly.

Foreign entity interest: Lupin Inc. owns Lupin Pharmaceuticals

LobbyistCovered position, as disclosed
KATHLEEN JAEGER New —

Contacted: State, Dept of (DOS); U.S. Trade Representative (USTR); White House Office; Commerce, Dept of (DOC); SENATE; Health & Human Services, Dept of (HHS)

Trade (domestic/foreign) TRD

Tarrifs - generic medicine

Foreign entity interest: Lupin Pharmaceuticals is owned by Lupin, Inc.

LobbyistCovered position, as disclosed
KATHLEEN JAEGER —

Contacted: White House Office; U.S. Trade Representative (USTR); Commerce, Dept of (DOC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.